<DOC>
	<DOCNO>NCT02683746</DOCNO>
	<brief_summary>This phase III , randomize , double-blind , multicenter , parallel group , repeat-dose , study 26 week duration evaluate efficacy , safety , tolerability pharmacodynamic response albiglutide liquid drug product relative commercial lyophilize drug product . The study specifically evaluate potential immunogenicity ( example [ e.g . ] incidence anti-drug antibody [ ADA ] ) injection site reaction ( ISRs ) . Albiglutide novel analogue glucagon-like peptide-1 ( GLP-1 ) sufficiently long half-life permit week injection . Currently , lyophilize albiglutide diluent provide dual chamber cartridge ( DCC ) , single-dose pen injector , require reconstitution prior use . A liquid formulation albiglutide enable commercialization liquid product single dose , ready-to-use prefilled syringe auto-injector . The primary hypothesis study test liquid drug product provide glycemic control ( measure HbA1c change baseline ) non-inferior lyophilized drug product period 26 week treatment subject T2DM . This study comprise 3 study period : screening ( 2 week ) , treatment ( 26 week ) subject enter extension study follow-up period ( 8 week ) . Approximately 300 subject randomize 1:1 ratio either Albiglutide active liquid auto-injector ( LAI ) plus Placebo lyophilize DCC pen injector ( lyophilize DCC PI ) ; , Albiglutide lyophilize DCC PI plus Placebo LAI .</brief_summary>
	<brief_title>Safety Efficacy Study Albiglutide Liquid Drug Product Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>18 80 year age inclusive Historical diagnosis type 2 diabetes mellitus ( T2DM ) ( least 3 month ) , experience inadequate glycemic control current regimen diet exercise stable maximal tolerate dose metformin , maintain approximately 8 week prior screen . HbA1c &gt; =7.0 percent ( % ) &lt; =10 % . Hemoglobin &gt; =11 gram per deciliter ( g/dL ) ( &gt; =110 gram per liter [ g/L ] ) males &gt; =10 g/dL ( &gt; =100 g/L ) female . Body mass index &lt; =40 kilogram per square meter ( kg/m^2 ) Male female Able willing provide inform consent . Type 1 diabetes mellitus History cancer full remission least 3 year screen . ( A history squamous cell basal cell carcinoma skin treat cervical intraepithelial neoplasia I II allow ) . Personal family history medullary thyroid carcinoma multiple endocrine neoplasia type 2 . History acute chronic pancreatitis . History thyroid dysfunction abnormal ( i.e. , outside normal reference range ) thyroid function test assess thyroid stimulate hormone screening . Severe gastroparesis , i.e. , require regular therapy within 6 month screen . History significant gastrointestinal ( GI ) surgery opinion investigator likely significantly affect upper GI pancreatic function History severe hypoglycemia unawareness Diabetic complication clinically significant abnormality . Clinically significant Cardiovascular ( CV ) and/or cerebrovascular disease within 3 month screen QT interval correct heart rate accord Fridericia 's formula ( QTcF ) &gt; 470 millisecond ( msec ) . ALT &gt; 2.5x upper limit normal range ( ULN ) bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current active liver biliary disease ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator assessment ) . Estimated glomerular filtration rate ( eGFR ) &lt; =30 milliliter ( mL ) /minute ( min ) /1.73 square meter ( m^2 ) ( calculate use Modification Diet Renal Disease [ MDRD ] formula ) screening . Fasting triglyceride level &gt; 750 milligram per deciliter ( mg/dL ) screening . Hemoglobinopathy may affect proper interpretation HbA1c . Medical psychiatric disorder would preclude effective participation study . Use oral systemically injected glucocorticoid within 3 month randomization high likelihood requirement prolong treatment ( &gt; 1 week ) 6 month follow randomization . Use dipeptidyl peptidaseIV inhibitor within 3 month randomization . History alcohol substance abuse within one year screening . Known allergy albiglutide product component ( include yeast human albumin ) , glucagonlike peptide1 ( GLP1 ) analogue , study medication 's excipients OR contraindication ( per prescribe information ) use potential study medication . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
	<keyword>Albiglutide</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Efficacy</keyword>
</DOC>